Merck KGaA (FRA:MRK) Given a €104.00 Price Target by Deutsche Bank Analysts

Deutsche Bank set a €104.00 ($120.93) price target on Merck KGaA (FRA:MRK) in a research note issued to investors on Monday, Borsen Zeitung reports. The brokerage currently has a neutral rating on the healthcare company’s stock.

A number of other equities analysts have also issued reports on MRK. JPMorgan Chase & Co. set a €100.00 ($116.28) target price on Merck KGaA and gave the company a neutral rating in a research report on Monday, November 11th. Credit Suisse Group set a €110.00 ($127.91) target price on Merck KGaA and gave the company a buy rating in a research report on Friday. Independent Research set a €103.00 ($119.77) target price on Merck KGaA and gave the company a neutral rating in a research report on Thursday, September 19th. Sanford C. Bernstein set a €114.00 ($132.56) target price on Merck KGaA and gave the company a neutral rating in a research report on Thursday, November 14th. Finally, UBS Group set a €96.00 ($111.63) target price on Merck KGaA and gave the company a neutral rating in a research report on Thursday, November 14th. One analyst has rated the stock with a sell rating, twelve have given a hold rating and five have given a buy rating to the company’s stock. The company has an average rating of Hold and a consensus price target of €103.06 ($119.84).

Shares of MRK traded up €0.05 ($0.06) during trading on Monday, reaching €108.20 ($125.81). The company’s stock had a trading volume of 546,294 shares. The company has a fifty day moving average of €105.73 and a two-hundred day moving average of €97.11. Merck KGaA has a twelve month low of €76.60 ($89.07) and a twelve month high of €115.00 ($133.72).

About Merck KGaA

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

See Also: What are the benefits of buying treasury bonds?

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.